Each ml contains:

Active substance:

Cloprostenol 250 µg

as Cloprostenol sodium 263 µg

Excipients:

Colourless solution.

For use in cattle

For the induction of luteolysis allowing resumption of oestrus and ovulation in cycling female cattle when used during dioestrus; synchronisation of oestrus (within 2 to 5 days) in groups of cycling females treated simultaneously; treatment of suboestrus and uterine disorders related to a functional or persistent corpus luteum (endometritis, pyometra); treatment of ovarian luteal cysts; induction of abortion until day 150 of pregnancy; expulsion of mummified foetuses; induction of parturition.

Pregnancy:

Do not use in pregnant animals, for which abortion or induction of parturition is not intended.

Lactation:

The veterinary medicinal product can be safely used during lactation.

For all indications: 2 ml corresponding to 0.5 mg cloprostenol/animal, injected intramuscularly.

In order to synchronise oestrus in groups of female cattle, it is recommended that the product is administered on two occasions with a treatment interval of 11 days.

As with parenteral administration of any substance, basic aseptic rules should be observed. The injection site must be thoroughly cleaned and disinfected in order to reduce the risk of infection with anaerobic bacteria.

People with known hypersensitivity to benzyl alcohol should avoid contact with the product. Do not eat, drink or smoke while handling the product. Direct contact with skin or mucous membranes of the user should be avoided. Prostaglandins of the F2α type may be absorbed through the skin and may cause bronchospasm or miscarriage. The product must be handled carefully to avoid ACCIDENTAL SELF-INJECTION OR SKIN CONTACT. Pregnant women, women in childbearing age, asthmatics and persons with other respiratory tract diseases should exercise caution when handling cloprostenol. Those persons should wear rubber (or plastic) gloves during administration of the product. Accidental spillage on the skin should be washed immediately with soap and water. In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.

Do not use in pregnant animals, for which induction of abortion or parturition is not intended. Do not use in animals with spastic diseases of the respiratory or gastrointestinal tract.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Cattle (cows):

* Anaphylactic-type reactions can be observed which might be life threatening and require rapid medical care.

** Anaerobic infection if anaerobic bacteria penetrate the tissue at injection site, in particular following intramuscular injection.

*** When used for induction of parturition and dependent on the time of treatment relative to the date of conception, the incidence of retained placenta may be increased.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.

Concurrent use of oxytocin and cloprostenol increases effects on the uterus. The activity of other oxytocic agents can be increased after the administration of cloprostenol.

Do not use in animals being treated with non-steroidal anti-inflammatories, as the synthesis of endogenous prostaglandins is inhibited.

Therapeutic tolerance in cattle is broad. Overdoses of more than 10 times are generally well tolerated. Large overdoses may cause transient diarrhoea. No antidotes are available.

An overdose will not accelerate corpus luteum regression.

Meat and offal: 2 days

Milk: Zero hours

Pharmacotherapeutic group: Prostaglandins

ATCvet code: QG02AD90

The Prostaglandin F2α analogue cloprostenol has luteolytic activity. Following its administration plasma progesterone falls to baseline levels. Progesterone concentrations start to decrease as early as 2 hours following injection. As a consequence, females with a sensitive CL (i.e. at least 5 days old) return to oestrus within 2-5 days of treatment and ovulate. The effect of cloprostenol on the smooth muscular system is similar to that of Prostaglandin F2α itself.

Following intramuscular injection, cloprostenol is rapidly adsorbed and peak cloprostenol concentrations are generally reached within the first 15 minutes after injection. Blood cloprostenol concentrations steadily decrease with a mean half life of approx. 56 min.

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

20 ml and 50 ml colourless glass vials (glass type I, Ph.Eur.) closed with a halogenobutyl rubber stopper, with or without teflon coating. An aluminium crimp cap with an integral plastic tamper-evident cover is fixed over the rubber stopper.

Secondary packaging: cardboard box.

Not all pack sizes may be marketed.

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf-life of the veterinary product after first opening the immediate packaging: 28 days.

Keep the vial in the outer carton.

Protect from light.

Medicines should not be disposed of via wastewater or household waste. Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

09 February 2006

July 2023

Vm 05653/3009

1ère avenue 2065 m –

L.I.D 06516 Carros

France